WJA  Vol.5 No.1 , March 2015
Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana
Abstract: Recent clinical trials have shown that a daily dose of oral TDF/FTC pre-exposure prophylaxis (PrEP) is effective in reducing human immunodeficiency (HIV) risk. Understanding trial participants’ perspectives about retention and PrEP adherence is critical to inform future PrEP trials and the scale-up and implementation of PrEP programs. We analyzed 53 in-depth interviews conducted in April 2010 with participants in the TDF2 study, a Phase 3, randomized, double-blind, place-bo-controlled clinical trial of daily oral TDF/FTC with heterosexual men and women in Francistown and Gaborone, Botswana. We examined participants’ knowledge, attitudes, and experiences of the trial, identified facilitators and barriers to enrollment and retention, and compared participant responses by study site, sex, and study drug adherence. Our findings point to several factors to consider for participant retention and adherence in PrEP trials and programs, including conducting pre-enrollment education and myth reduction counseling, providing accurate estimates of participant obligations and side effect symptoms, ensuring participant understanding of the effects of non-adherence, gauging personal commitment and interest in study outcomes, and developing a strong external social support network for participants.
Cite this paper: Toledo, L. , McLellan-Lemal, E. , Henderson, F. , Kebaabetswe, P. (2015) Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana. World Journal of AIDS, 5, 10-20. doi: 10.4236/wja.2015.51002.

[1]   Grant, R.M., Lama, J.R., Anderson, P.L., McMahan, V., Liu, A.Y., Vargas, L., et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 363, 2587-2599.

[2]   Baeten, J.M., Donnell, D., Ndase, P., Mugo, N.R., Campbell, J.D., Wangisi, J., et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England Journal of Medicine, 367, 399-410.

[3]   Thigpen, M.C., Kebaabetswe, P.M., Paxton, L.A., Smith, D.K., Rose, C.E., Segolodi, T.M., et al. (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine, 367, 423-434.

[4]   Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P.A., Leethochawalit, M., et al. (2013) Antiretroviral Prophylaxis for HIV Infection in Injecting Drug Users in Bangkok, Thailand (The Bangkok Tenofovir Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet, 381, 2083-2090.

[5]   Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 367, 411-422.

[6]   van der Straten, A., Stadler, J., Montgomery, E., Hartmann, M., Magazi, B., Mathebula, F., et al. (2014) Women’s Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa. PLoS ONE, 9, e89118.

[7]   Baeten, J.M., and Grant, R. (2013) Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know? Current HIV/AIDS Reports, 10, 142-151.

[8]   Koenig, L.J., Lyles, C. and Smith, D.K. (2013) Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis: Lessons Learned from Trials and Treatment Studies. American Journal of Preventive Medicine, 44, S91-S98.

[9]   US Public Health Service (2014) Preexposure Prophylaxis for the Prevention of HIV Infection in the United States 2014: A Clinical Practice Guideline.

[10]   Tangmunkongvorakul, A., Chariyalertsak, S., Amico, K.R., Saokhieo, P., Wannalak, V., Sangangam-sakun, T., et al. (2013) Facilitators and Barriers to Medication Adherence in an HIV Prevention Study among Men Who Have Sex with Men in the iPrEx Study in Chiang Mai, Thailand. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV, 25, 961-967.

[11]   Gilmore, H.J., Liu, A., Koester, K.A., Amico, K.R., McMahan, V., Goicochea, P., et al. (2013) Participant Experiences and Facilitators and Barriers to Pill Use among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. AIDS Patient Care and STDs, 27, 560-566.

[12]   Feldblum, P.J., Halpern, V., Lie, C.C., Obunge, O., Ogunsola, F., Ampofo, W. and Opoku, K. (2011) What Predicts Non-Retention in Microbicide Trials? Contemporary Clinical Trials, 32, 512-516.

[13]   Gappoo, S., Montgomery, E.T., Gerdts, C., Naidoo, S., Chidanyika, A., Nkala, B. and Ramjee, G., The MIRA Team (2009) Novel Strategies Implemented to Ensure High Participant Retention Rates in a Community Based HIV Prevention Effectiveness Trial in South Africa and Zimbabwe. Contemporary Clinical Trials, 30, 411-418.

[14]   Giguere, R., Zimet, G.D., Kahn, J.A., Dolezal, C., Leu, C.S., Mabragana, M., et al. (2013) The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico. World Journal of AIDS, 3.

[15]   Guest, G., MacQueen, K.M. and Namey, E.E. (2012) Applied Thematic Analysis. Sage Publications, Inc., Thousand Oaks.

[16]   MacQueen, K.M., McLellan, E., Kay, K. and Milstein, B. (1998) Codebook Development for Team-Based Qualitative Analysis. Field Methods, 10, 31-36.

[17]   Chesney, M.A., Ickovics, J.R., Chambers, D.B., Gifford, A.L., Neidig, J., Zwickl, B. and Wu, A.W. (2000) Self-Reported Adherence to Antiretroviral Medications among Participants in HIV Clinical Trials: The AACTG Adherence Instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. Psychological and Socio-Medical Aspects of AIDS/HIV, 12, 255-266.

[18]   Kebaabetswe, P.M., Stirratt, M.J., McLellan-Lemal, E., Henderson, F.L., Gray, S.C., Rose, C.E., et al. (2014) Factors Associated with Adherence and Concordance between Measurement Strategies in an HIV Daily Oral Tenofovir/ Emtricitabine as Pre-Exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. AIDS and Behavior, 1-12.

[19]   Amico, K.R., McMahan, V., Goicochea, P., Vargas, L., Marcus, J.L., Grant, R.M. and Liu, A. (2012) Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment. AIDS and Behavior, 16, 1243-1259.

[20]   Marcus, J., Buisker, T., Horvath, T., Amico, K., Fuchs, J., Buchbinder, S., Grant, R.M. and Liu, A.Y. (2014) Helping Our Patients Take HIV Pre-Exposure Prophylaxis (PrEP): A Systematic Review of Adherence Interventions. HIV Medicine, 15, 385-395.

[21]   Stirratt, M.J. and Gordon, C.M. (2008) Adherence to Biomedical HIV Prevention Methods: Considerations Drawn from HIV Treatment Adherence Research. Current HIV/AIDS Reports, 5, 186-192.

[22]   Krueger, K.P., Berger, B.A. and Felkey, B. (2005) Medication Adherence and Persistence: A Comprehensive Review. Advances in Therapy, 22, 313-356.

[23]   Van der Elst, E.M., Mbogua, J., Operario, D., Mutua, G., Kuo, C., Mugo, P., et al. (2013) High Acceptability of HIV Pre-Exposure Prophylaxis but Challenges in Adherence and Use: Qualitative Insights from a Phase I Trial of Intermittent and Daily PrEP in At-Risk Populations in Kenya. AIDS and Behavior, 17, 2162-2172.

[24]   Karim, Q.A., Kharsany, A., Naidoo, K., Yende, N., Gengiah, T., Omar, Z., et al. (2011) Co-Enrollment in Multiple HIV Prevention Trials—Experiences from the CAPRISA 004 Tenofovir Gel Trial. Contemporary Clinical Trials, 32, 333-338.

[25]   Ware, N.C., Wyatt, M.A., Haberer, J.E., Baeten, J.M., Kintu, A., Psaros, C., et al. (2012) What’s Love Got to Do with It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples. Journal of Acquired Immune Deficiency Syndromes, 59, 463-468.